JOHN SAMPSON, M.D.
Medical Practice in Durham, NC
License number
North Carolina 96-00716
Category
Medical Practice
Type
Neurological Surgery
Address
Address
2100 Erwin Rd Duke University Medical Ctr, Durham, NC 27710
Phone
(919) 684-9041
(919) 684-9045 (Fax)
(919) 684-9045 (Fax)
Personal information
See more information about JOHN SAMPSON at radaris.comName
Address
Phone
485 Crestside Dr SE, Concord, NC 28025
4309 Princeton Ave, Greensboro, NC 27407
416 Mock Mill Rd, Statesville, NC 28677
49 Lifting Fog Dr, Leicester, NC 28748
535 Norment Rd, Lumberton, NC 28360
Organization information
See more information about JOHN SAMPSON at bizstanding.comJohn Sampson MD,MHSC,PHD
30 Duke Medicine Cir, Durham, NC 27710
Industry:
Surgeons, Neurosurgeon
Phone:
(800) 266-3853 (Phone)
John Howard Sampson
Professional information
See more information about JOHN SAMPSON at trustoria.com
Dr. John Sampson, Durham NC - MD (Doctor of Medicine)
Dr. John Sampson, Durham NC - MD (Doctor of Medicine)
Specialties:
Neurosurgery
Address:
Durham Office
1 Duke Medical Ctr, Durham 27710
(919) 684-8111 (Phone), (919) 681-8679 (Fax)
Duke University Med Ctr Nrsgry
2100 Erwin Rd, Durham 27705
(919) 684-9041 (Phone)
1 Duke Medical Ctr, Durham 27710
(919) 684-8111 (Phone), (919) 681-8679 (Fax)
Duke University Med Ctr Nrsgry
2100 Erwin Rd, Durham 27705
(919) 684-9041 (Phone)
Certifications:
Neurosurgery, 2002
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Manitoba Faculty Of Medicine
Graduated: 1990
Duke University Med Center
University Of Manitoba Faculty Of Medicine
Graduated: 1990
Duke University Med Center
Allogeneic Cellular Vaccine
Allogeneic Cellular Vaccine
US Patent:
6503503, Jan 7, 2003
Filed:
May 13, 1997
Appl. No.:
08/855280
Inventors:
Darell D. Bigner - Mebane NC
John H. Sampson - Durham NC
David M. Ashley - Victoria, AU
Laura P. Hale - Hillsborough NC
John H. Sampson - Durham NC
David M. Ashley - Victoria, AU
Laura P. Hale - Hillsborough NC
Assignee:
Duke University - Durham NC
International Classification:
A61K 4800
US Classification:
424 9321, 424 932, 424 931, 435325, 4353201, 435455
Abstract:
Vaccination with an allogeneic cell line modified with genetic material encoding specific protein antigens is an effective technique for the delivery of protein antigens to the hosts antigen presentation system. The immune response generated by this vaccine is restricted by the major histocompatibility complex type of the host and not the vaccinating cell line. This immunization strategy may be used to treat or prevent tumors or infectious diseases of a mammal.
Novel Oxidoreductases For Enantioselective Reactions
Novel Oxidoreductases For Enantioselective Reactions
US Patent:
2013026, Oct 10, 2013
Filed:
Feb 27, 2013
Appl. No.:
13/778167
Inventors:
Hai Yan - Chapel Hill NC, US
Bryan Daehahn Choi - Durham NC, US
John Howard Sampson - Durham NC, US
Bryan Daehahn Choi - Durham NC, US
John Howard Sampson - Durham NC, US
International Classification:
C12N 9/00
US Classification:
435145, 435146, 435189, 43525421, 4353201, 536 232
Abstract:
Described herein are compositions and methods for generating oxidoreductases for enantioselective reactions. Described herein are compositions and methods for generating neomorphic (R)-2-hydroxyacid dehydrogenases capable of enzymatically converting a 1-carboxy-2-ketoacid to a 1-carboxy-(R)-2-hydroxyacid, or the reverse reaction. Illustrative examples include (a) (R)-2-hydroxyadipate dehydrogenase and uses thereof for converting 2-oxoadipate to (R)-2-hydroxyadipate, or the reverse reaction; and (b) (R)-2-hydroxyglutarate dehydrogenase and uses thereof for converting 2-oxoglutarate to (R)-2-hydroxyglutarate, or the reverse reaction. Also described herein are compositions and methods for generating non-natural microbial organisms to enzymatically convert 2-oxoadipate to (E)-2-hexenedioate or adipate, or to enzymatically convert 2-oxoglutarate to (E)-2-pentenedioate or glutarate, or the respective reverse reactions.
Compositions, Methods, And Kits For Eliciting An Immune Response
Compositions, Methods, And Kits For Eliciting An Immune Response
US Patent:
8425898, Apr 23, 2013
Filed:
Jun 19, 2009
Appl. No.:
12/488176
Inventors:
John H. Sampson - Durham NC, US
Duane A. Mitchell - Durham NC, US
Duane A. Mitchell - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 39/245
US Classification:
424 933, 4242301, 435 5, 435 71
Abstract:
The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.
Assay For Anti-Egfrviii Antibodies
Assay For Anti-Egfrviii Antibodies
US Patent:
2012011, May 10, 2012
Filed:
Jul 21, 2008
Appl. No.:
12/669374
Inventors:
Robert J. Schmittling - Hillsborough NC, US
Gary E. Archer - Hillsborough NC, US
John H. Sampson - Durham NC, US
Darell D. Bigner - Mebane NC, US
Gary E. Archer - Hillsborough NC, US
John H. Sampson - Durham NC, US
Darell D. Bigner - Mebane NC, US
Assignee:
Duke University - Durham NC
International Classification:
C40B 30/04, C40B 40/10
US Classification:
506 9, 506 18
Abstract:
Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen.
Bispecific Egfrviii Antibody Engaging Molecules
Bispecific Egfrviii Antibody Engaging Molecules
US Patent:
2012018, Jul 26, 2012
Filed:
Nov 15, 2011
Appl. No.:
13/296809
Inventors:
Darell D. BIGNER - Mebane NC, US
Chien-Tsun KUAN - Cary NC, US
John H. SAMPSON - Durham NC, US
Mingqing CAI - Danbury CT, US
Bryan D. CHOI - Durham NC, US
Chien-Tsun KUAN - Cary NC, US
John H. SAMPSON - Durham NC, US
Mingqing CAI - Danbury CT, US
Bryan D. CHOI - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 39/395, A61P 35/00, C12P 21/06, C07K 16/18, C07H 21/04
US Classification:
4241361, 5303873, 536 2353, 435 696
Abstract:
We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These are promising therapeutic agents.
Selection Of Antigen-Specific T Cells
Selection Of Antigen-Specific T Cells
US Patent:
2009000, Jan 1, 2009
Filed:
Jun 23, 2008
Appl. No.:
12/144318
Inventors:
Duane A. Mitchell - Durham NC, US
John Sampson - Durham NC, US
John Sampson - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
C12N 15/87, C12N 5/08
US Classification:
435455, 4353723
Abstract:
The requirement of T cell activation for efficient expression of genes after messenger ribonucleic acid (mRNA) transfection is leveraged to identify and enrich antigen-specific T cells responding to antigen-pulsed dendritic cells (DCs). RNA transfection of marker genes is used for the selection and enrichment of antigen-specific T cells for use in adoptive immunotherapy. RNA-modified T cells are also used for the generation of enhanced effector populations for use in adoptive immunotherapy. Genes whose transient expression may significantly enhance the in vivo function of T cells (i.e., migratory receptors, anti-apoptotic genes or cytokines enhancing T cell proliferation/differentiation) are used in this modality.
Concurrent Chemotherapy And Immunotherapy
Concurrent Chemotherapy And Immunotherapy
US Patent:
2009022, Sep 3, 2009
Filed:
Nov 2, 2006
Appl. No.:
12/092180
Inventors:
John H. Sampson - Durham NC, US
Darell D. Bigner - Mebane NC, US
Mitchell Duane - Durham NC, US
Amy Heimberger - Houston TX, US
Darell D. Bigner - Mebane NC, US
Mitchell Duane - Durham NC, US
Amy Heimberger - Houston TX, US
Assignee:
Duke University - Durham NC
Univeristy of Texas M.D. Anderson Cancer Center - Houston TX
Univeristy of Texas M.D. Anderson Cancer Center - Houston TX
International Classification:
A61K 39/00, A61K 38/10, A61K 38/17, A61P 35/00
US Classification:
4242771, 514 14, 514 6, 4241841
Abstract:
The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, in fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.
Trimodal Cancer Therapy
Trimodal Cancer Therapy
US Patent:
2011013, Jun 9, 2011
Filed:
Nov 16, 2010
Appl. No.:
12/947362
Inventors:
John H. Sampson - Durham NC, US
Duane A. Mitchell - Durham NC, US
Peter E. Fecci - Boston MA, US
Duane A. Mitchell - Durham NC, US
Peter E. Fecci - Boston MA, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241331, 4241581
Abstract:
Cancers are treated with three types of agents: a chemotherapeutic agent which induces lymphopenia; an inhibitory antibody to a surface marker on Treg cells; and an anti-cancer vaccine. This combination may lead to enhanced immune responses despite lymphodepletion.
Enhanced Immunological Responses
Enhanced Immunological Responses
US Patent:
2012024, Sep 27, 2012
Filed:
Dec 23, 2011
Appl. No.:
13/336590
Inventors:
John H. Sampson - Durham NC, US
Duane A. Mitchell - Durham NC, US
Duane A. Mitchell - Durham NC, US
Assignee:
DUKE UNIVERSITY - Durham NC
International Classification:
A61K 39/395, A61P 37/04
US Classification:
4241331, 4241581
Abstract:
Cancers and other diseases can be treated with two or three types of agents: an agent which induces lymphodepletion or lymphopenia; an inhibitory antibody to a surface marker on Treg cells; and optionally a specific antigen. This combination may lead to enhanced immune responses despite lymphodepletion or lymphopenia.